The RECOVERY Trial – two years on.
30 Mar, 2022 | 10:38h | UTCThe RECOVERY Trial – two years on – University of Oxford
Related:
[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19
Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19
Commentary on Twitter
"One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of researchers, doctors, nurses, statisticians and supporting staff."https://t.co/cDlCUkG4cD
— Martin Landray (@MartinLandray) March 28, 2022